Literature DB >> 24045886

Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Andrew A Udy1, Jason A Roberts, Jeffrey Lipman.   

Abstract

Successful antibiotic therapy in the critically ill requires sufficient drug concentrations at the site of infection that kill or suppress bacterial growth. The relationship between antibiotic exposure and achieving the above effects is referred to as pharmacokinetics/pharmacodynamics (PK/PD). The associated indices therefore provide logical targets for optimal antibiotic therapy. While dosing regimens to achieve such targets have largely been established from studies in animals and non-critically ill patients, they are often poorly validated in the ICU. Endothelial dysfunction, capillary leak, altered major organ blood flow, deranged plasma protein concentrations, extremes of body habitus, the application of extracorporeal support modalities, and a higher prevalence of intermediate susceptibility, independently, and in combination, significantly confound successful antibiotic treatment in this setting. As such, the prescription of standard doses are likely to result in sub-therapeutic concentrations, which in turn may promote treatment failure or the selection of resistant pathogens. This review article considers these issues in detail, summarizing the key changes in antibiotic PK/PD in the critically ill, and suggesting alternative dosing strategies that may improve antibiotic therapy in these challenging patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24045886     DOI: 10.1007/s00134-013-3088-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  126 in total

1.  Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion.

Authors:  Leonardo Lorente; Alejandro Jiménez; María M Martín; José Luis Iribarren; Juan José Jiménez; María L Mora
Journal:  Int J Antimicrob Agents       Date:  2009-01-15       Impact factor: 5.283

2.  Augmented creatinine clearance in traumatic brain injury.

Authors:  Andrew Udy; Robert Boots; Siva Senthuran; Janine Stuart; Renae Deans; Melissa Lassig-Smith; Jeffrey Lipman
Journal:  Anesth Analg       Date:  2010-11-03       Impact factor: 5.108

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion.

Authors:  J J De Waele; I Danneels; P Depuydt; J Decruyenaere; M Bourgeois; E Hoste
Journal:  Int J Antimicrob Agents       Date:  2013-02-12       Impact factor: 5.283

5.  Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Authors:  Eduardo Asín-Prieto; Alicia Rodríguez-Gascón; Iñaki F Trocóniz; Amaia Soraluce; Javier Maynar; José Ángel Sánchez-Izquierdo; Arantxazu Isla
Journal:  J Antimicrob Chemother       Date:  2013-08-01       Impact factor: 5.790

6.  Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients.

Authors:  Robert A Cherry; Soumitra R Eachempati; Lynn Hydo; Philip S Barie
Journal:  J Trauma       Date:  2002-08

7.  Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.

Authors:  Leonardo Lorente; Alejandro Jiménez; Salome Palmero; Juan José Jiménez; José Luís Iribarren; Melitón Santana; María M Martín; Maria L Mora
Journal:  Clin Ther       Date:  2007-11       Impact factor: 3.393

8.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

9.  Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance.

Authors:  R Brown; R Babcock; J Talbert; J Gruenberg; C Czurak; M Campbell
Journal:  Crit Care Med       Date:  1980-02       Impact factor: 7.598

10.  Intermittent administration of ceftazidime to burns patients: influence of glomerular filtration.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; G Houin; S Saivin
Journal:  Int J Clin Pharmacol Ther       Date:  2007-03       Impact factor: 1.366

View more
  59 in total

1.  Understanding antibiotic stewardship for the critically ill.

Authors:  J J De Waele; J Schouten; G Dimopoulos
Journal:  Intensive Care Med       Date:  2015-08-20       Impact factor: 17.440

Review 2.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

Review 3.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

Review 4.  [Tarragona strategy--appropriate antibiotic therapy in the ICU].

Authors:  L Engelmann; D V Schmitt
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-03-22       Impact factor: 0.840

5.  Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.

Authors:  Gabriela Campos de Oliveira Filgueira; Osmany Alberto Silva Filgueira; Daniela Miarelli Carvalho; Maria Paula Marques; Elaine Christine Dantas Moisés; Geraldo Duarte; Vera Lucia Lanchote; Ricardo Carvalho Cavalli
Journal:  Br J Clin Pharmacol       Date:  2017-01-29       Impact factor: 4.335

6.  Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).

Authors:  Cédric Bretonnière; Marc Leone; Christophe Milési; Bernard Allaouchiche; Laurence Armand-Lefevre; Olivier Baldesi; Lila Bouadma; Dominique Decré; Samy Figueiredo; Rémy Gauzit; Benoît Guery; Nicolas Joram; Boris Jung; Sigismond Lasocki; Alain Lepape; Fabrice Lesage; Olivier Pajot; François Philippart; Bertrand Souweine; Pierre Tattevin; Jean-François Timsit; Renaud Vialet; Jean Ralph Zahar; Benoît Misset; Jean-Pierre Bedos
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

7.  Ten tips for managing critically ill burn patients: follow the RASTAFARI!

Authors:  Matthieu Legrand; Anne Berit Guttormsen; Mette M Berger
Journal:  Intensive Care Med       Date:  2015-01-09       Impact factor: 17.440

Review 8.  Right first time!

Authors:  Emine Alp
Journal:  Ann Transl Med       Date:  2016-09

9.  Is there a role for continuous infusion of β-lactam antibiotics in severe sepsis?

Authors:  Angela Bates; Ari R Joffe
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

10.  Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study.

Authors:  Sébastien Bailly; Elodie Gautier-Veyret; Minh P Lê; Lila Bouadma; Olivier Andremont; Mathilde Neuville; Bruno Mourvillier; Romain Sonneville; Eric Magalhaes; Jordane Lebut; Aguila Radjou; Roland Smonig; Michel Wolff; Laurent Massias; Claire Dupuis; Jean-François Timsit
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.